A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries

Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2006, Vol.6 (1), p.53-59
Hauptverfasser: Colebunders, Robert, Moses, Kamya R, Laurence, John, Shihab, Hasan M, Semitala, Fred, Lutwama, Fred, Bakeera-Kitaka, Sabrina, Lynen, Lut, Spacek, Lisa, Reynolds, Steven J, Quinn, Thomas C, Viner, Brant, Mayanja-Kizza, Harriet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 59
container_issue 1
container_start_page 53
container_title The Lancet infectious diseases
container_volume 6
creator Colebunders, Robert
Moses, Kamya R
Laurence, John
Shihab, Hasan M
Semitala, Fred
Lutwama, Fred
Bakeera-Kitaka, Sabrina
Lynen, Lut
Spacek, Lisa
Reynolds, Steven J
Quinn, Thomas C
Viner, Brant
Mayanja-Kizza, Harriet
description Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not only that, but most HIV patients in resource-poor countries do not have access to such testing. We propose a new model for monitoring antiretroviral treatment in resource-limited settings that uses patients' clinical and treatment history, adherence to treatment, and laboratory indices such as haemoglobin level and total lymphocyte count to identify virological treatment failure, and offers patients future treatment options. We believe that this model can make an accurate diagnosis of treatment failure in most patients. However, operational research is needed to assess whether this strategy works in practice.
doi_str_mv 10.1016/S1473-3099(05)70327-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67597555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309905703273</els_id><sourcerecordid>67597555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-dde64d97f092820a683fa9572afeb76bd234c3f19f72d5aa778e3f2025494d0f3</originalsourceid><addsrcrecordid>eNqFkVtrFTEUhQdR7EV_ghIERR9Gc5195qmUUqtQ6EP1OeQkO5oykxyTTKX_3pwLFHzp094k314s1uq6N4x-ZpQNX26ZBNELOo4fqfoEVHDoxbPuuD3LXkoFz3f7HjnqTkq5o5QBo_Jld8QGAaCEOu78OYn4l8zJ4URqaksMNWVSfyO5DzlN6VewZiLofZv2gSRPTKwhY82pAe2rZjR1xlhJiCRjSUu22G9SU7FpiTUHLK-6F95MBV8f5mn38-vlj4tv_fXN1feL8-veSk5r7xwO0o3g6chXnJphJbwZFXDjcQ3D2nEhrfBs9MCdMgZghcJzypUcpaNenHYf9rqbnP4sWKqeQ7E4TSZiWooeQI2glGrgu__Au-Y7Nm-at3iZGEA0SO0hm1MpGb3e5DCb_KAZ1dsW9K4FvY1YU6V3Lejt3duD-LKe0T1eHWJvwPsDYEpL12cTbSiPHAigI_DGne05bJndB8y62IDRomsF2KpdCk9Y-Qfbk6TB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201613673</pqid></control><display><type>article</type><title>A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Colebunders, Robert ; Moses, Kamya R ; Laurence, John ; Shihab, Hasan M ; Semitala, Fred ; Lutwama, Fred ; Bakeera-Kitaka, Sabrina ; Lynen, Lut ; Spacek, Lisa ; Reynolds, Steven J ; Quinn, Thomas C ; Viner, Brant ; Mayanja-Kizza, Harriet</creator><creatorcontrib>Colebunders, Robert ; Moses, Kamya R ; Laurence, John ; Shihab, Hasan M ; Semitala, Fred ; Lutwama, Fred ; Bakeera-Kitaka, Sabrina ; Lynen, Lut ; Spacek, Lisa ; Reynolds, Steven J ; Quinn, Thomas C ; Viner, Brant ; Mayanja-Kizza, Harriet</creatorcontrib><description>Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not only that, but most HIV patients in resource-poor countries do not have access to such testing. We propose a new model for monitoring antiretroviral treatment in resource-limited settings that uses patients' clinical and treatment history, adherence to treatment, and laboratory indices such as haemoglobin level and total lymphocyte count to identify virological treatment failure, and offers patients future treatment options. We believe that this model can make an accurate diagnosis of treatment failure in most patients. However, operational research is needed to assess whether this strategy works in practice.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(05)70327-3</identifier><identifier>PMID: 16377535</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Anti-HIV Agents - administration &amp; dosage ; Anti-HIV Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Developing Countries ; Drug Monitoring ; Drug resistance ; Drug Resistance, Viral ; Hemoglobins - analysis ; HIV - drug effects ; HIV - genetics ; HIV - physiology ; HIV Infections - drug therapy ; HIV Infections - virology ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; LDCs ; Lymphocytes ; Medical sciences ; Patient Compliance ; Pharmacology. Drug treatments ; Reagents ; Treatment Failure ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load</subject><ispartof>The Lancet infectious diseases, 2006, Vol.6 (1), p.53-59</ispartof><rights>2006 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jan 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-dde64d97f092820a683fa9572afeb76bd234c3f19f72d5aa778e3f2025494d0f3</citedby><cites>FETCH-LOGICAL-c420t-dde64d97f092820a683fa9572afeb76bd234c3f19f72d5aa778e3f2025494d0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/201613673?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17370972$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16377535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Colebunders, Robert</creatorcontrib><creatorcontrib>Moses, Kamya R</creatorcontrib><creatorcontrib>Laurence, John</creatorcontrib><creatorcontrib>Shihab, Hasan M</creatorcontrib><creatorcontrib>Semitala, Fred</creatorcontrib><creatorcontrib>Lutwama, Fred</creatorcontrib><creatorcontrib>Bakeera-Kitaka, Sabrina</creatorcontrib><creatorcontrib>Lynen, Lut</creatorcontrib><creatorcontrib>Spacek, Lisa</creatorcontrib><creatorcontrib>Reynolds, Steven J</creatorcontrib><creatorcontrib>Quinn, Thomas C</creatorcontrib><creatorcontrib>Viner, Brant</creatorcontrib><creatorcontrib>Mayanja-Kizza, Harriet</creatorcontrib><title>A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not only that, but most HIV patients in resource-poor countries do not have access to such testing. We propose a new model for monitoring antiretroviral treatment in resource-limited settings that uses patients' clinical and treatment history, adherence to treatment, and laboratory indices such as haemoglobin level and total lymphocyte count to identify virological treatment failure, and offers patients future treatment options. We believe that this model can make an accurate diagnosis of treatment failure in most patients. However, operational research is needed to assess whether this strategy works in practice.</description><subject>Anti-HIV Agents - administration &amp; dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Developing Countries</subject><subject>Drug Monitoring</subject><subject>Drug resistance</subject><subject>Drug Resistance, Viral</subject><subject>Hemoglobins - analysis</subject><subject>HIV - drug effects</subject><subject>HIV - genetics</subject><subject>HIV - physiology</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>LDCs</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Reagents</subject><subject>Treatment Failure</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkVtrFTEUhQdR7EV_ghIERR9Gc5195qmUUqtQ6EP1OeQkO5oykxyTTKX_3pwLFHzp094k314s1uq6N4x-ZpQNX26ZBNELOo4fqfoEVHDoxbPuuD3LXkoFz3f7HjnqTkq5o5QBo_Jld8QGAaCEOu78OYn4l8zJ4URqaksMNWVSfyO5DzlN6VewZiLofZv2gSRPTKwhY82pAe2rZjR1xlhJiCRjSUu22G9SU7FpiTUHLK-6F95MBV8f5mn38-vlj4tv_fXN1feL8-veSk5r7xwO0o3g6chXnJphJbwZFXDjcQ3D2nEhrfBs9MCdMgZghcJzypUcpaNenHYf9rqbnP4sWKqeQ7E4TSZiWooeQI2glGrgu__Au-Y7Nm-at3iZGEA0SO0hm1MpGb3e5DCb_KAZ1dsW9K4FvY1YU6V3Lejt3duD-LKe0T1eHWJvwPsDYEpL12cTbSiPHAigI_DGne05bJndB8y62IDRomsF2KpdCk9Y-Qfbk6TB</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Colebunders, Robert</creator><creator>Moses, Kamya R</creator><creator>Laurence, John</creator><creator>Shihab, Hasan M</creator><creator>Semitala, Fred</creator><creator>Lutwama, Fred</creator><creator>Bakeera-Kitaka, Sabrina</creator><creator>Lynen, Lut</creator><creator>Spacek, Lisa</creator><creator>Reynolds, Steven J</creator><creator>Quinn, Thomas C</creator><creator>Viner, Brant</creator><creator>Mayanja-Kizza, Harriet</creator><general>Elsevier Ltd</general><general>Lancet Publishing Group</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries</title><author>Colebunders, Robert ; Moses, Kamya R ; Laurence, John ; Shihab, Hasan M ; Semitala, Fred ; Lutwama, Fred ; Bakeera-Kitaka, Sabrina ; Lynen, Lut ; Spacek, Lisa ; Reynolds, Steven J ; Quinn, Thomas C ; Viner, Brant ; Mayanja-Kizza, Harriet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-dde64d97f092820a683fa9572afeb76bd234c3f19f72d5aa778e3f2025494d0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-HIV Agents - administration &amp; dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Developing Countries</topic><topic>Drug Monitoring</topic><topic>Drug resistance</topic><topic>Drug Resistance, Viral</topic><topic>Hemoglobins - analysis</topic><topic>HIV - drug effects</topic><topic>HIV - genetics</topic><topic>HIV - physiology</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>LDCs</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Reagents</topic><topic>Treatment Failure</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colebunders, Robert</creatorcontrib><creatorcontrib>Moses, Kamya R</creatorcontrib><creatorcontrib>Laurence, John</creatorcontrib><creatorcontrib>Shihab, Hasan M</creatorcontrib><creatorcontrib>Semitala, Fred</creatorcontrib><creatorcontrib>Lutwama, Fred</creatorcontrib><creatorcontrib>Bakeera-Kitaka, Sabrina</creatorcontrib><creatorcontrib>Lynen, Lut</creatorcontrib><creatorcontrib>Spacek, Lisa</creatorcontrib><creatorcontrib>Reynolds, Steven J</creatorcontrib><creatorcontrib>Quinn, Thomas C</creatorcontrib><creatorcontrib>Viner, Brant</creatorcontrib><creatorcontrib>Mayanja-Kizza, Harriet</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colebunders, Robert</au><au>Moses, Kamya R</au><au>Laurence, John</au><au>Shihab, Hasan M</au><au>Semitala, Fred</au><au>Lutwama, Fred</au><au>Bakeera-Kitaka, Sabrina</au><au>Lynen, Lut</au><au>Spacek, Lisa</au><au>Reynolds, Steven J</au><au>Quinn, Thomas C</au><au>Viner, Brant</au><au>Mayanja-Kizza, Harriet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2006</date><risdate>2006</risdate><volume>6</volume><issue>1</issue><spage>53</spage><epage>59</epage><pages>53-59</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not only that, but most HIV patients in resource-poor countries do not have access to such testing. We propose a new model for monitoring antiretroviral treatment in resource-limited settings that uses patients' clinical and treatment history, adherence to treatment, and laboratory indices such as haemoglobin level and total lymphocyte count to identify virological treatment failure, and offers patients future treatment options. We believe that this model can make an accurate diagnosis of treatment failure in most patients. However, operational research is needed to assess whether this strategy works in practice.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>16377535</pmid><doi>10.1016/S1473-3099(05)70327-3</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1473-3099
ispartof The Lancet infectious diseases, 2006, Vol.6 (1), p.53-59
issn 1473-3099
1474-4457
language eng
recordid cdi_proquest_miscellaneous_67597555
source MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland
subjects Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral agents
Antiretroviral Therapy, Highly Active
Antiviral agents
Biological and medical sciences
CD4 Lymphocyte Count
Developing Countries
Drug Monitoring
Drug resistance
Drug Resistance, Viral
Hemoglobins - analysis
HIV - drug effects
HIV - genetics
HIV - physiology
HIV Infections - drug therapy
HIV Infections - virology
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
LDCs
Lymphocytes
Medical sciences
Patient Compliance
Pharmacology. Drug treatments
Reagents
Treatment Failure
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
title A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A50%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20model%20to%20monitor%20the%20virological%20efficacy%20of%20antiretroviral%20treatment%20in%20resource-poor%20countries&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Colebunders,%20Robert&rft.date=2006&rft.volume=6&rft.issue=1&rft.spage=53&rft.epage=59&rft.pages=53-59&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(05)70327-3&rft_dat=%3Cproquest_cross%3E67597555%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201613673&rft_id=info:pmid/16377535&rft_els_id=S1473309905703273&rfr_iscdi=true